Logo image of MNDR

MOBILE-HEALTH NETWORK SOLUTI (MNDR) Stock Fundamental Analysis

NASDAQ:MNDR - KYG622641176 - Common Stock

1.07 USD
+0 (+0.02%)
Last: 8/26/2025, 8:00:01 PM
Fundamental Rating

4

Taking everything into account, MNDR scores 4 out of 10 in our fundamental rating. MNDR was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of MNDR is average, but there are quite some concerns on its profitability. MNDR shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MNDR has reported negative net income.
MNDR Yearly Net Income VS EBIT VS OCF VS FCFMNDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -401.37%, MNDR is doing worse than 97.03% of the companies in the same industry.
MNDR has a Return On Equity of -678.46%. This is amonst the worse of the industry: MNDR underperforms 81.19% of its industry peers.
Industry RankSector Rank
ROA -401.37%
ROE -678.46%
ROIC N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNDR Yearly ROA, ROE, ROICMNDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

Looking at the Gross Margin, with a value of 17.39%, MNDR is doing worse than 62.38% of the companies in the same industry.
MNDR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MNDR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
MNDR Yearly Profit, Operating, Gross MarginsMNDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MNDR has more shares outstanding
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNDR Yearly Shares OutstandingMNDR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
MNDR Yearly Total Debt VS Total AssetsMNDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -15.72, we must say that MNDR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MNDR (-15.72) is worse than 92.08% of its industry peers.
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.72
ROIC/WACCN/A
WACC8.92%
MNDR Yearly LT Debt VS Equity VS FCFMNDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 2.04 indicates that MNDR has no problem at all paying its short term obligations.
MNDR's Current ratio of 2.04 is fine compared to the rest of the industry. MNDR outperforms 75.25% of its industry peers.
A Quick Ratio of 1.96 indicates that MNDR should not have too much problems paying its short term obligations.
MNDR has a Quick ratio of 1.96. This is in the better half of the industry: MNDR outperforms 75.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 1.96
MNDR Yearly Current Assets VS Current LiabilitesMNDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

MNDR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.98%.
Looking at the last year, MNDR shows a very strong growth in Revenue. The Revenue has grown by 25.66%.
MNDR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.52% yearly.
EPS 1Y (TTM)-342.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.69%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%-35.64%

3.2 Future

MNDR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.10% yearly.
Based on estimates for the next years, MNDR will show a very strong growth in Revenue. The Revenue will grow by 78.77% on average per year.
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MNDR Yearly Revenue VS EstimatesMNDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MNDR Yearly EPS VS EstimatesMNDR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MNDR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MNDR is valuated quite expensively with a Price/Forward Earnings ratio of 52.45.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MNDR is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of MNDR to the average of the S&P500 Index (22.67), we can say MNDR is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 52.45
MNDR Price Earnings VS Forward Price EarningsMNDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNDR Per share dataMNDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

MNDR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNDR's earnings are expected to grow with 42.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MNDR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOBILE-HEALTH NETWORK SOLUTI

NASDAQ:MNDR (8/26/2025, 8:00:01 PM)

1.07

+0 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-23 2024-10-23
Earnings (Next)N/A N/A
Inst Owners2.66%
Inst Owner Change-7.14%
Ins Owners26.23%
Ins Owner ChangeN/A
Market Cap4.68M
Analysts82.86
Price Target65.28 (6000.93%)
Short Float %1.34%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 52.45
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 2.7
EV/EBITDA N/A
EPS(TTM)-4.87
EYN/A
EPS(NY)0.02
Fwd EY1.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.17
BVpS0.58
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -401.37%
ROE -678.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.39%
FCFM N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover4.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.04
Quick Ratio 1.96
Altman-Z -15.72
F-ScoreN/A
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)101.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.69%
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)25.66%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%-35.64%
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-267.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-184.86%
OCF growth 3YN/A
OCF growth 5YN/A